Analyst Jason Butler of JMP Securities reiterated a Buy rating on Vigil Neuroscience Inc (VIGL – Research Report), retaining the price target of $23.00.
Jason Butler has given his Buy rating due to a combination of factors surrounding Vigil Neuroscience Inc’s promising clinical data and the potential of their lead drug candidate. The company’s presentations at the American Academy of Neurology (AAN) 2024 meeting were well-received, showcasing encouraging findings from their ILLUMINATE natural history study and Phase 2 IGNITE trial for the treatment of ALSP with their drug iluzanebart. This positive reception is bolstered by Vigil’s demonstration of biomarker changes that suggest a disease-modifying effect, a significant milestone in the treatment of mild and early-to-moderate ALSP.
Furthermore, the completion of enrollment for the IGNITE trial, surpassing the initial target, along with the favorable safety and tolerability profile of iluzanebart, strengthens the case for Vigil Neuroscience’s potential success. The correlation of MRI and fluid biomarker changes with disease progression and cognitive impairment, as observed in the ILLUMINATE study, reinforces the company’s approach. These factors, combined with the anticipation of the next data update, underpin Jason Butler’s confidence in the company and his Buy rating, with a maintained price target that reflects these optimistic developments.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Vigil Neuroscience Inc (VIGL) Company Description:
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families.
Read More on VIGL:
- Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
- Vigil Neuroscience’s Funding Peril: Navigating Market Turbulence in Equity Capital Raises
- Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Vigil Neuroscience sees cash runway into 2H25
- Vigil Neuroscience reports Q4 EPS (57c), consensus (53c)
